The Flash FFR Ⅱ Study

Not Applicable

Recruiting

• Conditions: Coronary Artery Disease; Coronary Stenosis; Myocardial Ischaemia; Unstable Angina Pectoris; Asymptomatic Ischemia; Stable Angina Pectoris; Acute Myocardial Infarction; Percutaneous Coronary Intervention; Coronary Circulation
• Interventions: Diagnostic Test: caFFR; Diagnostic Test: FFR

• Registration Number: NCT04575207
• Lead Sponsor: Peking University First Hospital

Brief Summary

The overall purpose of Flash FFR Ⅱ is to investigate whether coronary angiography-derived fractional flow reserve (caFFR), compared with fractional flow reserve (FFR) measured by a pressure wire, has non-inferior clinical effect and cost benefit in guiding the percutaneous coronary intervention (PCI) for patients with moderate coronary artery stenosis in terms of long-term clinical prognosis.

Detailed Description

Flash FFR Ⅱ is a prospective, multicenter, blinded, randomized, non-inferiority trial. Eligible patients with moderate coronary artery stenosis will be included in the study and randomly assigned to either caFFR-guided group or FFR-guided group. Participant caFFR or FFR will be used to guide percutaneous coronary intervention (PCI) strategy.

The rate of major cardiovascular adverse events (MACE) and the cost data will be collected during the long-term follow-up (2 years). MACE is defined as a composite of all-cause death, myocardial infarction (MI), unplanned revascularization. Clinical outcomes and cost-effectiveness will be compared between the two groups.

A subgroup analysis is pre-set and included in the protocol, including age, sex, body mass index, diabetes mellitus, smoking status, mean aortic pressure (resting state), acute coronary syndrome, left ventricular ejection fraction, lesion site, lesion stenosis severity, target vessel reference diameter, small vessel lesion, blood flow velocity, PCI mode, and so on.

The trial is equipped with a core laboratory. Some interesting sub-studies will be carried out, such as a comparison of laboratory and operator analysis results.

If the trial results show non-inferiority, it should be noted that caFFR can bring new benefits to both operators and patients as a new index of physiological assessment of coronary artery stenosis severity with the advantages of lower cost, less risk, faster time, and less use of resources.

Study Timeline

• Study First Submitted: 2020-09-22
• Study First Submitted QC: 2020-09-29
• Study First Posted: 2020-10-05
• Study Start: 2021-01-12
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-20
• Last Update Posted: 2023-03-21
• Primary Completion: 2023-12
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 2132

Inclusion Criteria

• General inclusion criteria:

  1. Age above 18 years old, no limit on the gender;
  2. Angiography is considered necessary and feasible by investigator, and PCI will be performed if necessary;
  3. Suspected coronary heart disease, stable angina pectoris, unstable angina pectoris, non-culprit vascular assessment in participants with acute non-ST-segment elevation myocardial infarction, and non-culprit vascular assessment in patients with previous ST-segment elevation acute myocardial infarction;
  4. Participants voluntarily participate in this clinical trial and sign informed consent form.

• Coronary angiography inclusion criteria:

The presence of at least one stenosis and meets the following imaging findings:

1. The degree of coronary artery stenosis≥50% and ≤90% by visual measurement;
2. The reference diameter of the stenotic segment≥2.25 mm by visual measurement;
3. The investigator visually observes the target vessel through angiographic images, and consider that PCI surgery is technically feasible.

Exclusion Criteria

• General exclusion criteria:

  1. Acute ST-segment elevation myocardial infarction within 6 days;
  2. Cardiogenic shock or left ventricular ejection fraction≤50%;
  3. eGFR < 30 mL/min (1.73 m2);
  4. Severe coagulation dysfunctions or bleeding disorders;
  5. Allergic to iodine contrast medium or contraindications for adenosine administration;
  6. Severe aortic stenosis;
  7. Life expectancy less than 1 year;
  8. Pregnant women or women planning a recent pregnancy;
  9. Participation in any other clinical trials of devices or drugs (ongoing or within the past 1 month);
  10. The investigator believes that the particitant has other conditions that are not suitable for clinical trials.

• Coronary angiography exclusion criteria:

  1. TIMI flow in the target vessel<grade III ;
  2. Presence of myocardial bridge and systolic compression ≥50% in the target vessel;
  3. Presence of artificial bypass in the target vessel;
  4. Left main coronary artery or right coronary artery ostial lesions;
  5. Stent implantation in the target vessel within 3 months;
  6. Target vessel provides collateral support to chronically total occluded vessels;
  7. Presence of factors affecting angiographic analysis and stenosis visualization, including incomplete vessel opacification, or overlap with other coronary branches of extreme vessel foreshortening.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
caFFR-guided	caFFR	Participants who are randomly assigned to caFFR-guided group will receive the detection of Coronary Angiography-Derived Fractional Flow Reserve (caFFR) Measurement System. The online caFFR value is used to guide the PCI strategy. If caFFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when caFFR \> 0.80.
FFR-guided	FFR	Participants who are randomly assigned to FFR-guided group will receive the detection of pressure wire. The FFR value is used to guide the PCI strategy. If FFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when FFR \> 0.80.

Primary Outcome Measures

Name	Time	Method
MACE	1 year	A composite of all-cause death, myocardial infarction (MI), and unplanned revascularization

Secondary Outcome Measures

Name	Time	Method
MACE（excluding PCI-related MI）	1 month, 1 year, 2 years	A composite of all-cause death, myocardial infarction (excluding PCI-related), and unplanned revascularization
Death	1 month, 6 months, 1 year, 2 years	Cardiovascular, non-cardiovascular, and undetermined death
MI	1 month, 6 months, 1 year, 2 years	Target vessel related and non-target vessel related MI
Target vessel revascularization (TVR)	1 month, 6 months, 1 year, 2 years	The ischemia driven and non-ischemia driven TVR
Any coronary artery revascularization	1 month, 6 months, 1 year, 2 years	The ischemia driven and non-ischemia driven revascularization
Analysis of participant discomfort during the operation (none/mild/moderate/severe )	During the operation	During the caFFR or FFR detection, the operator will ask the participant if there is discomfort (none/mild/moderate/severe ) and what kind of discomfort(such as palpitation, chest stuffy , nausea, dizziness, foreign body invasion ), and fill out a questionnaire after the operation.The discomfort of all participants caused by the use of drugs, intervention, etc. during the caFFR or FFR detection will be analyzed.
The changes of PCI strategy depending on caFFR/FFR information	During the operation	Before randomization,the operators will be asked to provide their planned treatment strategy based on the angiographic information alone.; After randomization and functional assessment,we will record how caFFR/FFR changed the treatment strategy.
Definite or probable stent thrombosis	1 month, 6 months, 1 year, 2 years	Definite and probable stent thrombosis during acute, sub-acute, late, and very late phase
Evaluation of health economics	1 month, 6 months, 1 year	Cost-utility analysis and computation of incremental cost-effectiveness ratio.

Trial Locations

Locations (13)

Zhongshan Hospital affiliated to Fudan University; 🇨🇳 Shanghai, Shanghai, China

Department of Cardiology, Peking University First Hospital; 🇨🇳 Beijing, China

Guangdong Provincial People's Hospital; 🇨🇳 Guangzhou, Guangdong, China

The University of Hong Kong Shenzhen hospital; 🇨🇳 Shenzhen, Guangdong, China

The People's Hospital of Hebi; 🇨🇳 Hebi, Henan, China

Affiliated Hospital of Yunnan University; 🇨🇳 Kunming, Yunnan, China

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University; 🇨🇳 Peking, Beijing, China

Peking University People's Hospital; 🇨🇳 Peking, Beijing, China

The First Affiliated Hospital of Xinxiang Medical College; 🇨🇳 Xinxiang, Henan, China

QILU Hospital of Shandong University; 🇨🇳 Jinan, Shandong, China

West China Hospital, Sichuan University; 🇨🇳 Chengdu, Sichuan, China

Jiangxi Provincial People's Hospital; 🇨🇳 Nanchang, Jiangxi, China

Xiamen Cardiovascular Hospital Xiamen University; 🇨🇳 Xiamen, Fujian, China